Original research article BACKGROUND: L-type calcium channels (LTCCs) play important roles in regulating cardiomyocyte physiology, which is governed by appropriate LTCC trafficking to and density at the cell surface. Factors influencing the expression, half-life, subcellular trafficking, and gating of LTCCs are therefore critically involved in conditions of cardiac physiology and disease.
M aintenance of calcium homeostasis is critical for preserving the physiology of the cell. A variety of complex mechanisms intervene in the regulation of intracellular levels of Ca 2+ and its compartmentalization between subcellular compartments. In the heart, Ca 2+ release from the sarcoplasmic reticulum (SR), the major intracellular Ca 2+ store, to the cytosol is regulated through a process called Ca 2+ -induced Ca 2+ release. 1,2 Ca 2+ -induced Ca 2+ release is initiated by the entry of Ca 2+ into cardiac cells through sarcolemmal voltage-dependent L-type Ca 2+ channels (LTCCs), which triggers the release of Ca 2+ from the SR to the cytoplasm through ryanodine receptor 2. A close association between LTCC and ryanodine receptor 2 is required for efficient Ca 2+ -in-duced Ca 2+ release and is dependent on the density and organization of LTCCs within the T-tubular invagination of the plasma membrane. 2 The increase in free intracellular Ca 2+ allows Ca 2+ to bind to troponin C, initiating muscle contraction. This is terminated subsequently by the removal of cytosolic Ca 2+ through its reuptake into the SR via the cardiac SR Ca 2+ -ATPase and, to a lesser extent, by other Ca 2+ transport systems. This process is a key regulator of cardiac excitation-contraction coupling and a major determinant for intrinsic physiologic properties of the beating heart.
Modifications in the appropriate trafficking of LTCC to and density at the cell surface and changes in its subcellular localization and gating properties can cause functional alterations in the overall inward Ca 2+ current (I Ca,L ) 3 and consequently the cellular Ca 2+ machinery. In line with this, acquired and genetically determined LTCC dysfunction has been found to be associated with various human diseases, 4 including life-threatening cardiovascular pathologies. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] LTCCs are expressed in all excitable cells (ie, striated, smooth muscle, and neuronal cells). 15 The cardiac LTCC is composed of the pore-forming Ca v α1.2 and the accessory Ca v β2 and Ca v α2δ subunits. [15] [16] [17] Ca v β2, the cytoplasmic chaperone of Ca v α1.2, is composed of a globular domain (including an Src homology 3 [SH3] and a guanylate kinase-like [GK] domain) and a C-terminal coiled-coil tail (C-tail) and belongs to the membrane-associated GK family, which is involved in intracellular signaling and the establishment/maintenance of cell polarity. 16 Ca v β2 binds to the pore unit at the α-interaction domain, 18 affecting its trafficking to the plasma-membrane, [19] [20] [21] its internalization, 22 and its gating properties. 17, 23 However, although LTCC channel physiology has been intensively studied during the last decades, more in-depth insights into the mechanisms regulating the trafficking and function of LTCCs are still required. Here, we unraveled new regulatory pathways modulating the LTCC life cycle and generated a mimetic peptide (MP) that, through multiple levels of regulation, specifically targets Ca v β2, thereby controlling LTCC levels at the plasma membrane. Additionally, we provide proof of concept for in vivo administration of MP as an effective therapeutic strategy for the treatment of cardiac disorders associated with LTCC abnormalities.
MethODs
Detailed procedures are provided in the online-only Data Supplement.
Plasmids
Yeast 2-hybrid bait constructs were generated in the pGBKT7 vector (Clontech), and the mouse adult heart cDNA library was generated with the Make Your Own Mate & Plate Library System (Clontech). For the nanoluciferase and bioluminescence clinical Perspective What is new?
• A tight control of the Ca 2+ cardiac machinery is essential for normal cardiac physiology. Alterations in the voltage-dependent L-type calcium channel (LTCC), the key mediator of intracellular Ca 2+ entry, are associated with various life-threatening cardiovascular conditions such as pathologic hypertrophy, atrial fibrillation, post-inflammatory cardiomiopathy, hypertension, and diabetic cardiomyopathy. The potential use of positive Ca 2+ modulators for the treatment of cardiovascular pathologies has received considerable attention during the past decades. However, hitherto, pharmacologic approaches aimed at enhancing Ca 2+ current and inotropism in systolic heart failure have frequently been found to favor arrhythmogenesis and diastolic dysfunction, thereby limiting their use in the clinic. • Here, we identified a novel peptidomimetic therapeutic tool for the treatment of cardiovascular diseases that, via an unconventional mechanism, bypasses the arrhythmogenic limitations of current channelactivator inotropes. In particular, by dissecting new regulatory pathways modulating the LTCC life cycle, we generated a mimetic peptide that, through multiple levels of regulation, specifically targets the LTCC Ca v β2 cytosolic chaperone, thereby controlling LTCC assembly and density at the plasma membrane while preserving its physiologic channel function.
What are the clinical implications?
• We provide proof of concept for the exploitation of a novel therapy based on mimetic peptide technology and demonstrate that cardiac dysfunctions (eg, diabetic cardiomyopathy) associated with LTCC abnormalities can be effectively treated by in vivo administration of the generated mimetic peptide. Thus, mimetic peptide technology associated with nanocarriers for safe and cardiac-specific delivery may provide novel innovative therapeutic tools for the treatment of cardiac diseases.
resonance energy transfer (BRET) assays, cDNAs were cloned into the pNLF1-N and pNLF1-N and the HaloTag-pFN21A vector (Promega), respectively.
Western and Dot Blot analyses
Ca v α1.2 Ca v β2 (S8b-1), HA, and transferrin receptor were from Abcam; c-myc 9E10 was from Santa Cruz; HP-1γ 42S2 came from Millipore; GAPDH 14C10 was purchased from Cell Signaling Technology; Polyaginine 9R was from Cell Applications; and goat anti-mouse and anti-rabbit horseradish peroxidase was purchased from Thermo Fisher Scientific. A rabbit polyclonal antibody against the phosphorylated Akt consensus site of Ca v β2 was generated by GenScript.
nanoluciferase assay
In NanoLuc Luciferase (Promega), HEK293 cells pretreated for 30 minutes with 20 µmol/L cycloheximide were transfected as described in the Results section. Time-course analysis was performed with a Synergy 4 instrument (BioTek).
nanoBret assay
In the NanoBRET Assay (Promega), HEK293-transfected cells were treated with 100 nmol/L NanoBRET 618 ligand, and signals were detected 5 hours after treatment. For the peptide-protein binding assay, tetramethylrhodamine peptides were used. Signals were detected with a Synergy 4 instrument (BioTek). We previously demonstrated that Ca v α1.2 total protein levels are affected by the phosphorylation status of Ca v β2 at the Akt consensus site in its C-tail. 24 To determine the mechanism by which phosphorylated Ca v β2 controls the Ca v α1.2 level, we performed yeast 2-hybrid screenings of human and mouse heart cDNA libraries using phosphomimetic Ca v β2 (Ca v β2-SE 24 ) as bait. Unexpectedly, several positive clones corresponded to the SH3 region in the globular domain of Ca v β2 ( Figure 1A) , and cotransformation assays confirmed the binding of Ca v β2-SE, but not wild-type Ca v β2, to the globular region of Ca v β2 ( Figure 1B) . The specificity of the interaction was further confirmed by coimmunoprecipitation assays ( Figure 1C ). Analysis of the Ca v β2 structure revealed a solvent accessible sequence within the minimal common region of the identified Ca v β2 clones ( Figure 1A ), which we predicted to be responsible for the binding to the Ca v β2 C-tail on Akt phosphorylation. Taken together, these results suggest that the Akt-dependent protective effect on Ca v α1.2 stability is not mediated through interaction with other proteins but relies entirely on Ca v β2 structural rearrangements, triggered by Akt-mediated phosphorylation of its C-allowing interaction with a minimal region within the Ca v β2-SH3 globular domain that we called the tail-interacting domain (TID).
To determine whether the TID directly affects Ca v α1.2 protein stability, we used site-specific mutagenesis to replace positively charged lysines (K) at positions 141, 149, and 161 in the TID sequence with glutamines (Q) to destroy any potential ionic interaction between the TID and the C-tail. In cells cotransfected with Ca v α1.2 and Ca v β2-SE, similar protein levels of Ca v α1.2 were found in the presence and absence of Akt activation (ie, with and without serum, corresponding to phosphorylated and nonphosphorylated Ca v β2, respectively; Figure 1F , inset), whereas significantly reduced Ca v α1.2 levels were found in cells cotransfected with K161Q-mutant Ca v β2-SE under serum free conditions ( Figure 1D ). Consistently, the K161Q mutation prevented the interaction with Ca v β2-SE in the yeast 2-hybrid system ( Figure 1E ), suggesting a direct role of the TID in the protective effect of Ca v β2-SE on Ca v α1.2 stability. Similarly, the intracellular Ca 2+ concentration was significantly higher in cells cotransfected with Ca v α1.2 and Ca v β2-SE compared with wild-type Ca v β2 after serum starvation, whereas cotransfection with K161Q-mutant Ca v β2-SE ablated this effect ( Figure 1F ). In addition, I Ca,L was significantly reduced in cells transfected with K161Q-mutant Ca v β2-SE compared with Ca v β2-SE (Figure 1G ). Taken together, these results provide evidence that the TID within the Ca v β2-SH3 domain plays a direct role in stabilizing Ca v α1.2. Mann-Whitney test). E, Yeast 2-hybrid cotransformation assay. Labels refer to bait and prey plasmids transformed into yeast cells. F, Top, Western blot analysis for the phosphorylation status of Ca v β2 at the Akt consensus site in total protein lysates from HEK293 cells transfected as indicated (n=3). Bottom, Intracellular Ca 2+ levels in serum starved HEK293 cells transfected as indicated (n=8; 1-way ANOVA). AU indicates arbitrary units. G, Ca 2+ current measurements in serum-starved tSA201 cells transfected as indicated (n=15). All data are shown as mean±SD. *P<0.05; **P<0.01; ***P<0.001.
MP affects ltcc Protein stability and Function in Vitro
We next designed an array of partially overlapping peptides covering the C-tail and tested their effect on Ca v α1.2 stability through binding to the Ca v β2-TID. Cotransfection of cells with Ca v α1.2, Ca v β2, and individual peptides, followed by Western blot analyses ( Figure 2A ) and intracellular Ca 2+ concentration measurements ( Figure 2B ), identified several peptides that efficiently regulated Ca v α1.2 protein amounts and increased intracellular Ca 2+ concentration without inducing apoptosis (Figure 2A ). For our subsequent studies, we selected peptide 11 designated as MP, the effect of which was most similar to that of Ca v β2-SE. Computational docking simulation of the interaction between the MP and the Ca v β2-TID ( Figure 2C Next, to facilitate intracellular uptake, MP was fused to an oligoarginine (R7W) cell-penetrating peptide. 25 The R7W was fused to the N-terminus of the MP, which, on the basis of the Ca v β2-MP 3D model ( Figure 2C ), was not predicted to create steric hindrance or to affect MP function. To monitor the extent and specificity by which R7W-MP binds to Ca v β2, we performed a BRET protein interaction assay between a Ca v β2-NanoLuc donor and increasing doses of R7W-MP or R7W-scramble peptide conjugated to the tetramethylrhodamine fluorophore (acceptor). This revealed binding of R7W-MP to Ca v β2 in a dose-dependent manner, a finding specific for the Ca v β2-SH3 domain and not the GK domain ( Figure 2D ). Dot blot analyses after Ca v β2 immunoprecipitation on lysates from cells transfected with Ca v β2 constructs and treated with R7W-peptides supported the above results ( Figure  IIA in the online-only Data Supplement). Furthermore, Figure 2 . the mimetic peptide (MP) r7W-MP binds to ca v β2 and affects ca v α1.2 protein stability and function.
A, Western blot analysis of Ca v α1.2 and Caspase 3 in total protein lysates from HEK293 cells transfected as indicated (n=3). B, Intracellular Ca 2+ levels in HEK293 cells transfected as indicated (n=8; 1-way ANOVA). C, Molecular model of the MP (orange) docked onto the tail-interacting domain (TID) region of Ca v β2 (yellow), revealing the formation of electrostatic interactions. D, Dose-dependent binding of R7W-MP-tetramethylrhodamine (TMR) and R7W-scramble (R7W-scr)-TMR to Ca v β2-NanoLuc, Src homology 3 (SH3)-NanoLuc, and guanylate kinase-like (GK)-NanoLuc as measured by bioluminescence resonance energy transfer assay in transfected HEK293 cells (n=6). E, Ca v α1.2 half-life measured by a NanoLuc luciferase assay. HEK293 cells were transfected with Ca v α1.2-NanoLuc and treated with incremental doses (0.12, 1.3, and 10,2 μmol/L) of R7W-MP and R7W-scr as indicated (n=6; 1-way ANOVA). F, Western blot analysis for Ca v α1.2 in total protein lysates from serum-starved HEK293 cells transfected and treated as indicated (n=4; Mann-Whitney test). G, Ca 2+ current measurements in tSA201 cells transfected and treated as indicated (n=15; 1-way ANOVA). All data are shown as mean±SD. *P<0.05; **P<0.01; ***P<0.001.
ORIGINAL RESEARCH ARTICLE 539 R7W-MP was found to colocalize with Ca v β2 in adult cardiomyocytes ( Figure IIB in the online-only Data Supplement). As expected, R7W-MP was shown to increase the half-life ( Figure 2E ) and total protein levels ( Figure  IIC in the online-only Data Supplement) of Ca v α1.2 in a dose-dependent manner. Replacement of either K161 in the TID sequence or its direct interacting residue in MP (E7) with glutamines (Q) ablated the protective effect of R7W-MP on Ca v α1.2 protein levels ( Figure 2F ) and halflife ( Figure IID in the online-only Data Supplement), confirming the specificity of the TID-MP interaction. R7W-MP, but not R7W-scramble, was found to efficiently preserve I Ca,L ( Figure 2G ) without affecting the steady-state voltage dependency of the channel under serum free conditions (data not shown).
r7W-MP Prevents Dynamin From Binding to ca v β2 and Protects ca v α1.2 From Protein Degradation
The Ca v β2-SH3 domain was previously shown to downregulate LTCC density at the plasma membrane through interaction with dynamin, a GTPase involved in endocytosis and vesiculation. 22 Furthermore, a dynaminspecific inhibitor was found to protect Ca v α1.2 from protein degradation 22 and to extend its half-life (data not shown). This led us to question whether R7W-MP might compete with dynamin for binding to the Ca v β2-SH3 domain, thereby enhancing the Ca v α1.2 half-life. To test this hypothesis, we performed a BRET assay that revealed that R7W-MP indeed prevents dynamin from binding to Ca v β2 ( Figure 3A ). In addition, we demonstrated that Ca v β2 dissociates from Ca v α1.2 when bound to dynamin, whereas R7W-MP recovered the interaction of Ca v α1.2 with its chaperone ( Figure 3B ). Finally, in a cell surface protein biotinylation assay, a significant reduction in biotinylated Ca v α1.2 (membrane fraction) was found in cells cotransfected with dynamin, an effect that was fully counteracted by R7W-MP ( Figure 3C ).
r7W-MP Facilitates ca v α1.2 chaperoning to the Plasma Membrane by Preventing Kir/gem Binding to ca v β2
Kir/Gem, together with Rad, Rem, and Rem2, is a member of the RGK small GTP-binding protein family 26 known to negatively affect the amount of LTCCs at the cell surface. 27, 28 In particular, overexpression of Kir/ Gem in Xenopus oocytes was reported to compromise the association of Ca v β3 with Ca v α1.2 and to prevent the trafficking of the channel to the plasma membrane by sequestering Ca v β3 in intracellular compartments. 27 From this finding and evidence that Kir/Gem binds to Ca v β3 through a region within its SH3 domain, 29 we hypothesized that R7W-MP promotes anterograde trafficking of Ca v α1.2 by preventing Kir/Gem from complexing with Ca v β2. A BRET interaction assay confirmed the binding of Kir/Gem to Ca v β2, which was compromised by R7W-MP ( Figure 4A ). In addition, the association of Ca v β2 with Ca v α1.2, which was drastically affected by the presence of Kir/Gem, was gradually recovered by R7W-MP ( Figure 4B ). The above results were supported by a surface protein biotinylation assay showing that R7W-MP treatment is sufficient to prevent the Kir/Gem-mediated reduction of Ca v α1.2 at the plasma membrane ( Figure 4C ). 
r7W-MP Prevents Kir/gem-Mediated relocation of ca v β2 to the nucleus and Promotes cacna1 expression
Members of the RGK family show several nuclear import signals and have been reported to sequester and shuttle Ca v β3 and Ca v β4 from the cytoplasm to the nucleus. 30, 31 In addition, Ca v β1b, Ca v β4, and Ca v β3 were shown to interact with nuclear proteins and to modulate gene expression. In particular, the Ca v β4 short splice variant in brain was found to interact with the nuclear heterochromatin protein 1γ (HP1γ), 30 a member of the chromatin organization modifier superfamily, negatively regulating gene expression. 32 Thus, we hypothesized that, when bound to Kir/Gem, cytoplasmic Ca v β2 relocates to the nucleus, where it affects the transcription of a specific set of genes through recruitment of HP1γ. As predicted, overexpression of Kir/Gem in HL-1 cardiac cells resulted in the translocation of Ca v β2 from the cytosol/plasma membrane to the nucleus, where it was found to colocalize with HP1γ ( Figure 5A ). The specific interaction between Ca v β2 and HP1γ was confirmed by BRET ( Figure 5B ) and coimmunoprecipitation ( Figure 5C ) assays, whereas R7W-MP prevented the interaction (Figure 5B and 5C) . In contrast, Ca v β2 did not interact with bromodomain 4, 33 an epigenetic factor that facilitates transcriptional activation ( Figure III in the online-only Data Supplement). Taken together, these data point to a specific interaction between the nucleus-relocalized Ca v β2 and HP1γ that is potentially required for the regulation of specific genes.
In muscle progenitor cells, Ca v β1 was recently shown to translocate to the nucleus and to regulate gene expression by recognizing noncanonical heptameric sites at the promoter region of a number of genes. 34 To determine whether nuclear Ca v β2 might play a similar role and be part of a negative feedback loop in cardiac cells by regulating genes encoding LTCC subunits, we performed promoter analysis that identified 3 and 1 noncanonical sequences in the promoter region of Cacna1c (encoding Ca v α1.2) and Cacnb2 (encoding Ca v β2), respectively ( Figure 5F and data not shown). Consistently, Ca v α1.2 RNA levels were found to be reduced in Kir/Gem-transfected HL-1 cells (causing translocation of Ca v β2 to the nucleus), whereas Ca v α1.2 expression was recovered by R7W-MP treatment ( Figure 5D ). In contrast, Ca v β2 expression was unaltered under all analyzed conditions (data not shown). Cotransfection with HP1γ-specific RNAi ( Figure IV in the online-only Data Supplement) prevented the reduction in Ca v α1.2 RNA levels ( Figure 5E ), demonstrating that the ability of nuclear Ca v β2 to repress LTCC pore unit expression is dependent on its interaction with HP1γ. Consistent with a direct role of nuclear Ca v β2 in regulating Cacna1c gene expression, chromatin immunoprecipitation with Ca v β2 antibody, followed by quantitative polymerase chain reaction analysis for the above promoter sequences revealed enrichment for the NC1 site at the Cacna1c promoter, which was prevented by R7W-MP treatment ( Figure 5F ). Furthermore, a luciferase-based promoter assay confirmed the negative regulatory effect of nuclear Ca v β2 on Cacna1 gene expression ( Figure 5G ), supporting the idea that relocalized Ca v β2 contributes to adjusting channel density in cells via a negative feedback loop.
r7W-MP restores cardiac Function in Vivo through Modulation of ltcc
Our next objective was to explore the use of R7W-MP for potential cardiac treatments in vivo. After dot blot analysis confirming the delivery of administered R7W-MP to the heart, the effect of R7W-MP on cardiac function was monitored ( Figure VA in the online-only Data Supplement). In vivo echocardiographic analyses revealed no differences between groups ( Table I in To investigate the potential therapeutic application of R7W-MP, we assessed its effect in a mouse model of streptozotocin-induced diabetes mellitus in which alteration of cardiac contractility and reduced LTCC density are secondary consequences of the disease 10, [35] [36] [37] [38] [39] (Figure 6A  and 6B and Tables II and III in the online-only Data Supplement) . Notably, R7W-MP treatment normalized ventricular systolic function and restored Ca v α1.2 protein levels in diabetic mice ( Figure 6A and 6B and Table III in A, Immunofluorescence of Ca v β2 (red) and heterochromatin protein 1γ (HP1γ; green) in HL-1 cells transiently transfected with Ca v β2-DsRed and Kir/Gem constructs and treated as indicated. Bar=10 μm (n=15). B, Ca v β2-Hp1γ protein interaction as measured by bioluminescence resonance energy transfer (BRET) assay in HEK293 cells transfected with Ca v β2-NanoLuc and Hp1γ-Halo and treated as indicated (n=6). C, Coimmunoprecipitation assay from the nuclear fraction of HEK293 cells, confirming the interaction of Hp1γ with Ca v β2. Representative experiments are shown (n=4). Cells were transfected as indicated. D, Quantitative reverse transcription-polymerase chain reaction analysis for Ca v α1.2 expression in HL1 cells transfected as indicated (n=4). E, qRT-PCR analysis for Ca v α1.2 expression in HL1 cells transfected as indicated (n=12). F, Top, Consensus Ca v β2 DNA-binding motifs in the promoter of the cacna1c gene. Bottom, Chromatin immunoprecipitation with Ca v β2 antibody in HL-1 cells treated as indicated (n=3). G, Promoter luciferase assay in HEK293 cells transfected as indicated. All data are shown as mean±SD. Peptide doses were 0.12, 1.3, and 10.2 μmol/L. R7W-scr indicates R7W-scramble. *P<0.05; **P<0.01 (Mann-Whitney test). of cardiomyocytes from the same mice revealed restoration of cell contractility, systolic Ca 2+ amplitude, and I Ca,L ( Figure 6C and 6D) , as well as normalization of I CaL inactivation kinetics ( Figure VI in the online-only Data Supplement), in R7W-MP treated mice. These results show the ability of R7W-MP to reduce LTCC turnover and to correct myocardial dysfunction associated with diabetes mellitus, a secondary complication of diabetes mellitus.
On the basis of these outcomes, we explored the potential translatability of our results and retrospectively analyzed left ventricular biopsies from diabetic and nondiabetic cardiomyopathy patients with aortic stenosis undergoing aortic valve replacement. Interestingly, we found a direct linear correlation between the total amount of Ca v α1.2 and the Akt-dependent phosphorylation status of Ca v β2 (Figure 7 ).
DiscussiOn
The Ca v β2 LTCC subunit is known to dictate the appropriate chaperoning of Ca v α1.2 to and density at the cell surface, which is necessary for initiating Ca 2+ influx and thus proper excitation-contraction coupling in the heart. Under stress conditions, the SH3-dependent scaffolding properties of Ca v β2 are altered, thus affecting the assembly, intracellular mobility, and function of the LTCC multiprotein complex. Here, we provide new insights into Ca 2+ channel physiology and demonstrate that the density of the pore unit is regulated by molecular reorganization of Ca v β2, which is initiated by Aktmediated phosphorylation of its C-terminal tail, allowing it to bind to the central SH3 domain. From this finding, we generated an MP that, by targeting the binding region (TID) within the SH3 domain of Ca v β2, increases Ca v α1.2 density at the plasma membrane. Mechanistically, our results point toward a complex regulatory system that involves multiple levels of regulation ( promoter. This last mechanism shows that Ca v β2 plays a critical role in a previously unknown negative feedback pathway controlling the highly regulated expression of LTCC. Future work should address whether nuclear Ca v β2 might be involved in the modulation of a family of genes encoding proteins associated with the regulation of Ca 2+ handling, sarcomeric assembly, and Ca 2+ sensitivity of myofilaments, thereby affecting contractility. 34, [40] [41] [42] Our results provide the basis for the development of a potential novel therapy for the treatment of car- diac disorders associated with reduced LTCC density. The MP generated in this study falls in the class of positive Ca 2+ modulators, which has received considerable attention in the past decades. However, although remarkably efficient at enhancing Ca 2+ current and inotropism in systolic heart failure, this class of compounds was also found to favor arrhythmogenesis, thereby limiting their clinical use. For instance, the deleterious effects of the LTCC-activator BAYK8644 was shown to be due at least partly to unwanted modification of gating kinetics of the LTCC pore and Ca 2+ -independent effects on ryanodine receptor gating, increasing resting SR Ca 2+ release. 43 In contrast, the MP described here acts unconventionally by direct chaperone-mediated modulation of LTCC density and, via its direct action on the life cycle of the channel, restores physiologic levels of LTCC only when its density at the plasma membrane is reduced. Additionally, we found that P-Ca v β2 levels, which, as expected, were reduced in diabetic mice, were normalized to control levels after MP treatment. This leads to the intriguing hypothesis that, by binding to Ca v β2, MP might facilitate the proximity or availability of the LTCC chaperone for the active Akt at the plasma membrane. If this is the case, in addition to its effect on Ca v α1.2 density at the plasma membrane, MP stimulates the "physiologic" Akt-dependent stabilizing effect on LTCC density and function, 24 thereby initiating a possible forward mechanism. More dedicated and in-depth studies are required to address this possibility. Although an MPbased therapy might be envisioned, as also supported by the striking linear correlation between phosphorylated Ca v β2 and Ca v α1.2 density in our preliminary retrospective studies of human patient biopsies, further compound optimization, toxicity studies, and largerscale prospective analyses are required. For instance, the detrimental effects previously observed with supraphysiologic levels of Ca v β2 and Ca v α1.2 [44] [45] [46] [47] [48] raise the question of whether MP administration may cause similar issues. However, although further and more exhaustive studies are required (ie, short-to long-term pharmacokinetic analysis), it is promising that MP administration did not result in any abnormal increase in Ca v α1.2 density or I Ca,L . Additionally, MP did not affect Ca v β2 protein levels in either stressed or unstressed conditions. Another issue is the broad tissue distribution of Ca v β2, necessitating careful re-evaluation of the nature and type of carrier to use because the current R7W carrier is not specific to the heart and thus may also have potential effects at other locations such as the vasculature or the sympathetic nervous system. In this regard, the recent development of novel drug carriers (ie, cell-specific aptamers 49 or functionalized nanoparticles 50 ) might allow specific delivery to the heart and thus minimization of short-or long-term secondary side effects.
cOnclusiOn
This study identifies new regulatory mechanisms controlling the LTCC life cycle and provides proof of concept for a novel therapy for the treatment of cardiac conditions associated with reduced LTCC density.
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